Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.32 |
| ▸ | MTOR | P42345 | 6/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23798067 | 0.89 | CACNA1B (0.35) | CACNA1BCYP3A4BRD4BRD2BRD9 | |
| SCHEMBL25844139 | 0.79 | BRD9 (0.39) | CYP3A4BRD4BRD2BRD9BRD7 | |
| SCHEMBL25091781 | 0.77 | CACNA1B (0.45) | CACNA1BCYP3A4BRD4BRD2BRD9 | |
| SCHEMBL23798059 | 0.75 | CACNA1B (0.38) | CACNA1BCYP3A4BRD4BRD2BRD9 | |
| SCHEMBL25091954 | 0.75 | BRD4 (0.38) | BRD4BRD2BRD9BRD7 | |
| SCHEMBL23783402 | 0.74 | BRD4 (0.43) | BRD4BRD2BRD9BRD7 | |
| SCHEMBL30031484 | 0.74 | BRD4 (0.43) | BRD4BRD2BRD9BRD7 | |
| SCHEMBL23783182 | 0.74 | BRD4 (0.43) | BRD4BRD2BRD9BRD7 | |
| SCHEMBL25091776 | 0.72 | CACNA1B (0.44) | CACNA1BCYP3A4BRD4BRD9PIK3CA | |
| SCHEMBL25091093 | 0.71 | METAP2 (0.43) | CACNA1BCYP3A4BRD4BRD9PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CACNA1B 4261/4885CYP3A4 4588/4885BRD4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.